NOVARTIS Logo
CH0012005267
904278
NVSEF

NOVARTIS

Previsión

Comprar
  5
Mantener
  14
Vender
  1

Debates en la comunidad

  • Traducido del alemán

    Cartera en preparación para la jubilación

    g guba IV en Portfolio Roasts

    11 49
  • Dividenden[wachstums]portfolio ab 2026

    Gil Gil I en Schnack

    1 7
  • Umfrage: Der 2025er FOMO-Beichtstuhl

    Jan Jan IV en Schnack

    4 4
  • Portfolio Altersvorsorge

    M Maja V en Portfolio Roasts

    7 17
  • Novo Nordisk

    s sanzen I en Schnack

    3 20

  • Novartis expects annual revenue growth of 5% through 2031

    Novartis expects currency-adjusted annual revenue growth of 5% from 2026 to 2031, down from its previous forecast of 5% to 6%. Its target of an adjusted operating margin of more than 40% by 2029 remains unchanged. The company now expects peak sales of $8 billion for Kesimpta and $5 billion each for Scemblix and Leqvio. Despite recent setbacks in its development pipeline, Novartis is sticking to its acquisition strategy. » Más en wiwo.de


  • Novartis: two tumor cases could be linked to gene therapy Zolgensma

    Novartis reports that signs were found in two children suggesting the vector used in the gene therapy Zolgensma may have integrated genetic material into DNA. Since the initial approval in 2019, a total of nine tumor reports have been received from patients treated with Zolgensma; the therapy has been given to more than 6,000 children. The FDA is now reviewing the risk of benign and malignant tumors and possible regulatory actions. Novartis emphasizes that authorities have been informed and that the benefit in approved indications continues to outweigh the risks; no neoplasms have been reported so far for Itvisma. » Más en n-tv.de


  • Novartis raises outlook after Q3 thanks to higher sales and core profit

    Novartis reports a Q3 net sales increase of 4% to $14.5bn and an 11% rise in core operating profit to $6.0bn; core earnings per share rose to $2.46. The company has raised its 2026 guidance for core operating results to around last year’s level up to low single-digit growth (previously a low single-digit decline). Reported operating income, however, was hit by a $1.9bn impairment on the product candidate del‑desiran, causing it to fall 59% to $1.8bn. Novartis cites lower costs and productivity improvements as support for the core result. » Más en finanzen.net


  • Novartis stops late-stage study of remibrutinib in generalized myasthenia gravis

    Novartis has terminated the late-stage study of remibrutinib in generalized myasthenia gravis due to an anticipated failure to meet efficacy endpoints; no safety concerns were identified. The decision does not affect ongoing studies in other indications. Novartis emphasizes that despite this setback, remibrutinib could still become the company’s highest-grossing drug; the compound is already approved as Rhapsido for chronic urticaria and also showed positive results in MS studies. » Más en finanzen.net


  • Novartis raises profit forecast after strong adjusted result despite large impairments

    Novartis reported a third-quarter adjusted operating result that rose 11% to just over $6 billion and has raised its profit outlook for 2026: adjusted operating profit is now expected to either stagnate or grow in the low single digits. Group profit, however, fell by around 60% to $1.84 billion operating and $1.2 billion net due to impairments, of which $1.9 billion related to a failed Del‑Desiran study. Revenue grew 4% to about $14.5 billion, supported by older products and Cosentyx, and Novartis says it will stick to its 2025–2030 mid‑term plan despite setbacks in late‑stage trials. » Más en finanzen.net

En 2026, NOVARTIS ya ha pagado 4,09 € en dividendos. El último pago fue en marzo.

Datos financieros

En el último trimestre, NOVARTIS tuvo unos ingresos de 12,83 mil M € y un beneficio neto de 1061,71 M €

(EUR) septiembre de 2026
YoY
Ingresos 12,83 mil M 4,84 %
Beneficio bruto 9671,11 M 4,90 %
Beneficio neto 1061,71 M 68,28 %
EBITDA 5470,19 M 9,90 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
270,8 mil M €
Número de acciones
1888,62 M
Máximo/mínimo de 52 semanas
148,61 € - 107,88 €
Rentabilidad por dividendo
2,81 %
Dividendos TTM
4,09 €
Beta
0,47
Ratio P/E
30,16
Ratio PEG
-1,03
Ratio P/B
7,95
Ratio P/S
5,39

Perfil de la empresa

Novartis AG investiga, desarrolla, fabrica y comercializa productos sanitarios en todo el mundo. La empresa opera a través de dos segmentos, Innovative Medicines y Sandoz. El segmento Innovative Medicines ofrece medicamentos de prescripción para pacientes y profesionales sanitarios. También proporciona productos de oftalmología, neurociencia, inmunología, hepatología, dermatología, respiratorio, cardiovascular, renal y metabolismo. El segmento Sandoz desarrolla, fabrica y comercializa medicamentos en forma farmacéutica terminada; principios activos y formas farmacéuticas terminadas de productos farmacéuticos de molécula pequeña para terceros; y medicamentos genéricos de venta minorista y anti-infecciosos. También proporciona principios activos farmacéuticos e intermedios, principalmente antibióticos; productos basados en proteínas u otra biotecnología, incluidos biosimilares; y servicios de fabricación biotecnológica. Novartis AG tiene un acuerdo de licencia y colaboración con Alnylam Pharmaceuticals para desarrollar, fabricar y comercializar inclisirán; y una colaboración clínica con Kura Oncology, Inc. para evaluar la combinación de tipifarnib y alpelisib en pacientes con carcinoma de células escamosas de cabeza y cuello. La compañía se constituyó en 1996 y tiene su sede en Basilea, Suiza.

Nombre
NOVARTIS
CEO
Vasant Narasimhan
Sede Basel, bs
Suiza
Sitio web
Sector
Salud
Industria
Productos farmacéuticos
Salida a bolsa
02/08/2018
Empleados 75.267

Símbolos bursátiles

Bolsa Símbolo
Pnk
NVSEF
SIX
NOVN.SW
Düsseldorf
NOT.DU
Hamburg
NOT.HM
London
0QLR.L
München
NOT.MU
🍪

Parqet  usa cookies. Más información